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Abstract
Natural killer (NK) cells are regulated by interactions between polymorphic killer immunoglobulin-like receptors (KIR) and
human leukocyte antigens (HLA). Genotypic combinations of KIR3DS1/L1 and HLA Bw4-80I were previously shown to
influence HIV-1 disease progression, however other KIR genes have not been well studied. In this study, we analyzed the
influence of all activating and inhibitory KIR, in association with the known HLA inhibitory KIR ligands, on markers of disease
progression in a West African population of therapy-naı ¨ve HIV-1 infected subjects. We observed a significant association
between carriage of a group B KIR haplotype and lower CD4+ T cell counts, with an additional effect for KIR3DS1 within the
frame of this haplotype. In contrast, we found that individuals carrying genes for the inhibitory KIR ligands HLA-Bw4 as well
as HLA-C1 showed significantly higher CD4+ T cell counts. These associations were independent from the viral load and
from individual HIV-1 protective HLA alleles. Our data suggest that group B KIR haplotypes and lack of specific inhibitory KIR
ligand genes, genotypes considered to favor NK cell activation, are predictive of HIV-1 disease progression.
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Introduction
Natural killer (NK) cells play an important role in the innate
immune response against viruses and tumors, and in the regulation
of the subsequent adaptive immune responses [1]. Their activity is
controlled by an integration of signals from many inhibitory and
activating receptors, including the killer immunoglobulin-like
receptors (KIR) [2,3]. KIR contain two or three external
immunoglobulin-like domains (2D, 3D) with either long (L) or
short (S) cytoplasmic tails corresponding to their function as
inhibitory or activating receptors, respectively. Several inhibitory
KIR have well-defined human leukocyte antigen (HLA) class I
ligands. Mutually exclusive groups of HLA-C molecules with
asparagine or lysine at position 80, termed C1 and C2, ligate
inhibitory KIR2DL1, KIR2DL2, and KIR2DL3 [4]. A group of
HLA-B molecules expressing the serologically defined Bw4 epitope
recognize inhibitory KIR3DL1, with those with an isoleucine at
position 80 (Bw4-80I) showing stronger inhibition than those with a
threonine at this position (Bw4-80T) [5]. Both KIR and HLA loci
show extreme population diversity and rapid evolution, suggesting
that they are under pathogen-mediated selection and that they
influence disease outcome at the individual level [6]. Indeed, several
recent epidemiological studies have associated KIR/HLA compound
genotypes with diseases as diverse as infection, autoimmune and
inflammatory conditions, cancer, and reproductive failure [7].
HIV-1 infected patients show a large variation in disease courses
[8]. A number of recent studies provide evidence that KIR and
HLA loci play an important role in this. Flores-Villanueva et al.
first found that HIV-1 patients with homozygous Bw4 showed
delayed progression to AIDS [9]. Martin et al. confirmed this but
indicated that the association was derived completely from an
epistatic interaction of Bw4-80I with KIR3DS1, suggesting a model
in which NK cells activated through KIR3DS1 confer protection
from HIV-1 disease [10]. However, subsequent studies could not
confirm the KIR3DS1/Bw4-80I association [11,12], and no study
to date has been able to prove Bw4-80I as a true ligand for
KIR3DS1 [13–16]. The interpretation of the KIR3DS1/Bw4-80I
interaction was further complicated by a recent study of the same
patient cohorts showing high expression alleles of inhibitory
KIR3DL1 in combination with Bw4-80I to also slow down disease
progression [17]. Thus, it remains unclear how exactly KIR/HLA
interactions influence HIV-1 disease outcome, and how NK cells
are involved in this [18].
Few studies have analyzed KIR genes other than KIR3DS1 and
KIR3DL1 in the context of HIV-1 disease. Up to 14 different
functionalKIRgeneshavebeenidentifiedwhich,asaresultofstrong
interlocus linkage disequilibrium, segregate in two broad haplotypes
termed group A and group B [19,20]. Consequently, association
analyseswith single KIRgeneslikely dependonthe KIRhaplotypein
which they occur. In this study, we analyzed the influence of all
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class I inhibitory KIRligands,onmarkers ofdisease progressionina
population of West African HIV-1 infected subjects.
Materials and Methods
Study subjects
Eighty one HIV-1 infected female sex workers attending a
confidential clinic in Abidjan, Co ˆte d’Ivoire between January 1997
and May 2000 were studied cross-sectionally. A subset of 20 HIV-
1 infected female sex workers enrolled for follow-up and paid
between 2 and 4 visits to the clinic spanning a period of up to 18
months. All subjects were therapy-naı ¨ve at the time of enrolment
and during follow-up.
Ethics Statement
The study was approved by ethical committee of the Ministry of
Health, Co ˆte d’Ivoire, the ethical committee of the Institute of
Tropical Medicine, Antwerp, Belgium, and by the Institutional
Review Board of the Centers for Disease Control and Prevention,
Atlanta, GA. All subjects gave written informed consent prior to
enrolment.
Laboratory methods
Whole blood was drawn in EDTA tubes (Becton Dickinson).
Plasma was tested for HIV infection by ELISA and Western blot.
CD4+ T cell counts were determined in whole blood using a
FACScan flow cytometer (Becton Dickinson). HIV-1 viral load
was quantified in plasma by the Amplicor HIV-1 Monitor assay,
version 1.5 (Roche). Peripheral blood mononuclear cells were
separated from whole blood by gradient centrifugation and stored
in liquid nitrogen.
KIR and HLA class I genotyping
Genomic DNA was extracted from peripheral blood mononu-
clear cells using a QIAamp DNA blood mini kit (Qiagen). KIR
typing was performed by PCR with sequence specific primers like
previously reported [21]. KIR haplotypes were assigned by using
the current working definition available at the website of the
European Bioinformatics Institute (http://www.ebi.ac.uk/ipd/
kir). Group B haplotypes are characterized by one or more of the
following genes: KIR2DL2, KIR2DL5, KIR2DS1, KIR2DS2,
KIR2DS3, KIR2DS5 and KIR3DS1. Group A haplotypes are
characterized by the absence of all of these genes, and contain
one or more of the following genes: KIR2DL1, KIR2DL3,
KIR3DL1, and KIR2DS4. KIR genotypes consist of two KIR
haplotypes. AA genotypes are identified by the absence of all group
B haplotype genes. AB and BB genotypes are characterized by the
presence of at least one group B haplotype gene. AB and BB
genotypes cannot easily be distinguished and are collectively
annotated as Bx. HLA-B and HLA-C typing was performed by
PCR with sequence specific oligonucleotides (Gen-Probe) on a
Luminex platform, which gives a DNA-based typing result at the
level of 2 digits and permits to distinguish Bw4-80I and Bw4-80T
from Bw6, and C1 from C2. High resolution typing of HLA-B*58
positive samples was performed by sequencing-based typing using
the AlleleSEQR HLA-B sequencing kit (Atria Genetics). DNA
sequences were detected on an automated fluorescent DNA
sequencer. HLA-B alleles were assigned up to six digits with the
help of ASSIGN 3.5 software.
Statistical methods
The subjects’ first CD4+ T cell count and HIV-1 plasma viral
load at the clinic were used in the cross-sectional analyses. The
effect of single KIR and HLA genes and KIR/HLA combinations
was assessed by linear regression analysis using log transformed
CD4+ T cell counts and viral load levels as the dependent
variables. Model selection was guided by the Akaike information
criterion (AIC), which assesses the fit between the data and the
model with a penalty for the number of parameters (i.e. favoring
the more parsimonious model). Longitudinal changes in the CD4+
T cell count were examined by mixed-effects linear regression
analysis with log transformed CD4+ T cell counts as the
dependent variable. Statistical analyses were performed with R
version 2.11.1 [22].
Results
Study population
HIV-1 infected female sex workers included in the study had a
median age of 26 years (interquartile range (IQR), 21–32) and they
reported a median duration of commercial sex work of 24 months
(IQR, 12–48). At the time of enrollment, the women showed a
median CD4+ T cell count of 523 cells/ml (IQR, 363–775) and a
median HIV-1 plasma viral load of 4.8 log10 RNA copies/ml
(IQR, 4.0–5.4). All subjects were therapy-naı ¨ve at the time of
enrolment and during follow-up.
Group B KIR haplotype genes are associated with lower
CD4+ T cell counts
First we investigated whether the extensive variability in KIR
gene content was associated with the CD4+ T cell count or plasma
viral load of the HIV-1 infected subjects (Table 1a). The presence
of KIR2DL2, KIR2DL5, KIR2DS3, and KIR3DS1 was associated
with significantly lower CD4+ T cell counts. These genes are all
specific to the group B KIR haplotype and, accordingly, subjects
with a KIR Bx genotype (i.e., those carrying one or two group B
haplotypes) showed a significantly lower CD4+ T cell count. No
such associations were found for the viral load, although trends
were seen for a number of group B KIR haplotype genes mirroring
the effects on the CD4+ T cell count. To investigate whether
individual group B haplotype genes showed effects on the CD4+ T
cell count beyond that of the Bx genotype, we analyzed them
together by multivariate linear regression (Table 2a). Only the
addition of KIR3DS1 resulted in a better fit of the model relative to
that with Bx alone (AIC of 156 vs. 158). These data show that
HIV-1 infected subjects carrying a group B KIR haplotype have
lower CD4+ T cell counts (Fig. 1A), and even more so if they also
have KIR3DS1 within the frame of this haplotype.
Inhibitory KIR ligand genes HLA-Bw4 and HLA-C1 are
associated with higher CD4+ T cell counts
Next, we investigated whether inhibitory KIR ligand genes were
associated with the CD4+ T cell count or plasma viral load of the
HIV-1 infected subjects. Subjects with Bw4 or C1 showed a trend
towards higher CD4+ T cell counts, with no effects on the viral
load (Table 1b). Interestingly, the effects of Bw4 and C1 on the
CD4+ T cell count became statistically significant when combined
in a multivariate model (Table 2b). Addition of a Bw4:C1
interaction term, denoting the simultaneous occurrence of Bw4
and C1, abrogated the individual effects of Bw4 and C1, indicating
that they were derived from subjects harboring both genes. On its
own, the Bw4:C1 interaction term explained the variation in CD4+
T cell counts best. These data show that HIV-1 infected subjects
carrying inhibitory KIR ligand genes Bw4 as well as C1 have
higher CD4+ T cell counts than those lacking either Bw4 or C1
(Fig. 1B). Two member alleles of Bw4, B*57 and B*58:01, are
known to display individual HIV-1 protective effects in African
KIR and HLA Genotypes in HIV-1 Disease
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CD4+ T cell counts and slightly lower viral load levels while no
such effects were seen for B*58:01 (Table 1c). Adjustment for both
B*57 and B*58:01 did little to abrogate the observed effects of Bw4
(1.21-fold; 95% CI, 0.85–1.74; p=0.285) or Bw4:C1 (1.47-fold;
95% CI, 1.06–2.03; p=0.045), suggesting that Bw4 acts at least in
part independently from B*57 and B*58:01.
KIR and HLA genes have both synergistic and
independent effects on the CD4+ T cell count
The protective effects of C1 and Bw4 on the CD4+ T cell counts
could result from its known interactions with KIR. To test this, we
investigated whether their effects could be abrogated by addition of
KIR:HLA interaction terms to the multivariate linear regression
models (Table 2c). Functional studies have shown that C1 binds to
inhibitory KIR2DL2 and KIR2DL3, while Bw4 binds to inhibitory
KIR3DL1 [4,5,24]. C1 and Bw4 have also been suggested to ligate
activating KIR2DS2/KIR2DS3 and KIR3DS1, respectively, but
this could not be confirmed to date [13–16,25]. We could not detect
statistical interaction of C1 with KIR2DL2 or KIR2DL3:t h e
interaction terms did not abrogate the C1 effects. However, trends
towards statistical interaction were observed for C1 with KIR2DS2
and KIR2DS3: in both cases the interaction terms showed protective
effects at the cost of C1. These models indicate that the negative
effects of KIR2DS2 and KIR2DS3 are dampened in the presence of
C1 (KIR2DS2: 0.59-fold in the absence versus 0.83-fold in the
presence of C1; KIR2DS3: 0.53-fold in the absence versus 0.93-fold
in the presence of C1), and that this capacity explains most of the
protective effect of C1. Because of the low numbers of subjects with
KIR3DS1 or without KIR3DL1 in our study population, we were not
able to calculate interactions of Bw4 with KIR3DL1 or KIR3DS1.
Next, we investigated whether the best-fitting KIR and HLA
combinations were independent of each other by analyzing them
together in multivariate linear regression models (Table 2d).
Overall, the effects of Bx and Bw4:C1 genotypes were found to be
independent, with no signs of interaction. Consequently, a better fit
of the data can be expected for combinations of these genotypes.
Indeed, thecombinationofBx andBw4:C1showeda majorincrease
in fit relative to that of Bw4:C1 alone, and even more so if KIR3DS1
was added to the model (AIC values of 142, 138 and 136,
respectively). The additive effects of Bx and Bw4:C1 are shown in
Fig. 1C, with HIV-1 patients possessing a KIR Bx genotype in the
absence of Bw4:C1 showing the lowest CD4+ T cell counts.
Carriage of a Bx genotype in absence of Bw4:C1 is
associated with faster CD4+ T cell decline
The low CD4+ T cell counts associated with a Bx genotype in
absence of Bw4:C1 could result from a higher rate of CD4+ T cell
Table 1. Univariate effects of KIR and HLA genes on the CD4+ T cell count and HIV-1 viral load level of 81 HIV-1 infected subjects.
Frequency n (%) CD4+ T cell count HIV-1 viral load
Fold difference (CI) AIC p Fold difference (CI) AIC p
a. KIR genes and genotypes
2DL1 77 (95) 1.46 (0.75–2.82) 163 0.260 4.27 (0.60–30.4) 202 0.144
2DL2 48 (59) 0.70 (0.53–0.93) 158 0.015 1.36 (0.56–3.30) 204 0.485
2DL3 63 (78) 1.07 (0.76–1.51) 164 0.702 1.13 (0.40–3.20) 204 0.811
2DL5 45 (56) 0.74 (0.56–0.98) 160 0.039 1.99 (0.84–4.71) 202 0.114
3DL1 80 (99) 0.54 (0.15–1.98) 163 0.345 10.0 (0.21–480) 203 0.239
2DS1 9 (11) 1.00 (0.63–1.59) 164 0.990 0.91 (0.23–3.59) 204 0.892
2DS2 42 (52) 0.78 (0.58–1.03) 161 0.077 0.98 (0.41–2.33) 204 0.961
2DS3 25 (31) 0.72 (0.53–0.97) 160 0.031 1.59 (0.63–4.03) 203 0.323
2DS4 79 (98) 1.14 (0.45–2.87) 164 0.784 9.75 (0.64–149) 201 0.101
2DS5 24 (30) 0.81 (0.59–1.10) 162 0.171 1.64 (0.64–4.19) 203 0.300
3DS1 5 (6.2) 0.51 (0.29–0.92) 159 0.025 1.96 (0.33–11.7) 204 0.454
AA 28 (35) 1.47 (1.10–1.96) 158 0.010 0.61 (0.25–1.53) 203 0.290
Bx 53 (65) 0.68 (0.51–0.91) 158 0.010 1.63 (0.65–4.04) 203 0.290
b. KIR ligand genes
Bw4 63 (78) 1.24 (0.88–1.74) 163 0.222 0.90 (0.32–2.53) 204 0.835
Bw6 56 (69) 1.07 (0.78–1.46) 164 0.671 1.01 (0.40–2.58) 204 0.981
Bw4-80I 58 (72) 1.19 (0.87–1.64) 163 0.274 1.00 (0.38–2.60) 204 1.000
Bw4-80T 7 (8.6) 1.08 (0.65–1.81) 164 0.761 0.69 (0.15–3.20) 204 0.632
C1
a 52 (71) 1.31 (0.94–1.83) 146 0.105 0.98 (0.35–2.76) 188 0.972
C2 66 (81) 0.97 (0.67–1.41) 164 0.880 0.87 (0.29–2.63) 204 0.798
c. HLA alleles
B*57 3 (3.7) 1.63 (0.77–3.47) 163 0.200 0.28 (0.03–2.73) 203 0.272
B*58:01 10 (13) 0.99 (0.64–1.54) 163 0.959 1.29 (0.33–5.06) 201 0.711
Data are calculated by linear regression analysis using log transformed CD4+ T cell counts and HIV-1 viral load levels as the dependent variables. CI, 95% confidence
interval; AIC, Akaike information criterion for goodness of fit; p, statistical significance.
adata available for 73 of 81 subjects. p values,0.05 are in bold type.
doi:10.1371/journal.pone.0017043.t001
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longer total duration of infection, a distinction that cannot be
made by cross-sectional analyses. The total duration of infection is
not available for this population of HIV-1 seroprevalent female sex
workers, but it can be estimated by the total duration of
commercial sex work which constitutes the main risk factor for
HIV-1 infection in this population. No differences in duration of
commercial sex work were observed between subjects with or
without Bx (median values of 25 vs 22 months, p=0.392) or
Bw4:C1 (median value of 24 months for both groups, p=0.588)
Table 2. Multivariate effects of KIR and HLA genes on the CD4+ T cell count of 81 HIV-1 infected subjects.
Term 1 Term 2 Term 3 Model
Fold difference (CI) p Fold difference (CI) p Fold difference (CI) P AIC p
a. KIR combinations
Bx+2DL2 0.75 (0.41–1.38) 0.358 0.89 (0.50–1.61) 0.703 159 0.035
Bx+2DL5 0.68 (0.41–1.12) 0.127 1.00 (0.62–1.62) 0.983 160 0.037
Bx+2DS2 0.65 (0.42–1.02) 0.061 1.05 (0.69–1.61) 0.813 159 0.036
Bx+2DS3 0.74 (0.53–1.04) 0.078 0.83 (0.59–1.17) 0.286 158 0.021
Bx+2DS5 0.69 (0.50–0.96) 0.030 0.97 (0.68–1.36) 0.840 159 0.037
Bx+3DS1 0.72 (0.54–0.96) 0.025 0.58 (0.34–1.03) 0.063 156 0.007
b. HLA combinations
a
Bw4+C1 1.48 (1.00–2.19) 0.049 1.46 (1.04–2.05) 0.030 144 0.038
Bw4+Bw4:C1 1.02 (0.66–1.56) 0.945 1.46 (1.04–2.05) 0.030 144 0.038
C1+Bw4:C1 0.98 (0.64–1.52) 0.945 1.48 (1.00–2.19) 0.049 144 0.038
Bw4:C1 1.47 (1.10–1.97) 0.010 142 0.010
c. KIR/HLA interactions
a
2DL2+C1+2DL2:C1 0.76 (0.43–1.36) 0.349 1.35 (0.78–2.32) 0.277 0.92 (0.46–1.82) 0.797 145 0.056
2DL3+C1+2DL3:C1 1.12 (0.55–2.29) 0.756 1.26 (0.60–2.66) 0.535 1.06 (0.46–2.44) 0.891 150 0.343
2DS2+C1+2DS2:C1 0.59 (0.34–1.04) 0.071 1.04 (0.62–1.73) 0.880 1.41 (0.73–2.74) 0.305 146 0.076
2DS3+C1+2DS3:C1 0.53 (0.31–0.92) 0.024 0.96 (0.62–1.50) 0.854 1.76 (0.89–3.46) 0.102 145 0.049
d. KIR/HLA combinations
a
Bx+Bw4:C1+Bx:Bw4:C1 0.63 (0.41–0.98) 0.041 1.29 (0.79–2.10) 0.297 1.18 (0.65–2.15) 0.585 140 0.005
Bx+Bw4:C1 0.69 (0.51–0.93) 0.015 1.44 (1.09–1.91) 0.012 138 0.002
Bx+3DS1+Bw4:C1 0.73 (0.54–0.97) 0.033 0.53 (0.29–0.98) 0.044 1.39 (1.05–1.84) 0.021 136 ,0.001
Data are calculated by multivariate linear regression analysis using log transformed CD4+ T cell counts as the dependent variable. The estimated effects of the
respective terms in the models are shown. Interaction terms, denoting the simultaneous occurrence of two genes, are annotated with ‘‘:’’.
aData available for 73 of 81 subjects. CI, 95% confidence interval; AIC, Akaike information criterion for goodness of fit; p, statistical significance.
doi:10.1371/journal.pone.0017043.t002
Figure 1. Effect of KIR and HLA genotypes on the CD4+ T cell count of HIV-1 infected subjects. (A) Effect of AA versus Bx genotype (n=81).
(B) Combined effect of inhibitory KIR ligand genes Bw4 and C1 (n=73). Bw4:C1 denotes the simultaneous occurrence of Bw4 and C1. (C) Combined
effect of Bx and Bw4:C1 genotypes (n=73). P values represent the statistical significance of the linear regression models using log-transformed CD4+
T cell counts as the dependent variable. Horizontal lines represent median values.
doi:10.1371/journal.pone.0017043.g001
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work affect the associations between Bx or Bw4:C1 and the CD4+
T cell count (Bx: 0.68-fold; 95% CI, 0.51–0.91; p=0.010; Bw4:C1:
1.46-fold; 95% CI, 1.08–1.97; p=0.013). Next, we analyzed
longitudinal changes in the CD4+ T cell count for a subset of 20
HIV-1 infected female sex workers with available follow up by
mixed-effects linear regression analysis (Fig. 2). Subjects with a Bx
genotype showed a statistically significant decline in CD4+ T cell
count; this was not found for subjects with an AA genotype. Lack of
Bw4:C1 did not result in a statistically significant decline in CD4+
T cell count on its own, but when combined with the presence of a
Bx genotype, it provided the strongest effect. Together, these
analyses suggest that the observed associations between Bx and
Bw4:C1 and the CD4+ T cell count do not result from differences
in the time since infection but from differences in the rate of CD4+
T cell decline during follow-up.
Discussion
Genotypic combinations of KIR3DS1/L1 and HLA Bw4-80I
were previously shown to influence HIV-1 disease progression,
however other KIR genes have not been well studied. Therefore,
we analyzed all activating and inhibitory KIR, in association with
the known inhibitory KIR ligands, in a population of West African
HIV-1 infected subjects.
We first found that HIV-1 infected subjects with a group B KIR
haplotype showed markedly lower CD4 counts and faster CD4 count
decline than those without. Significant differences were observed for
the individual group B haplotype genes KIR2DL2, KIR2DL5, KIR2DS3
and KIR3DS1,w i t hKIR3DS1 showing an additional effect to that of
the group B haplotype. These data confirm previous findings from
Gaudieri et al., who found HIV-1 disease promoting effects for
several group B haplotype genes including KIR3DS1 [11], and from
Martin et al. who noted faster disease progression among carriers of
KIR3DS1 in the absence of HLA Bw4-80I [10].
Next, we found that HIV-1 infected subjects carrying genes for
both Bw4 and C1 showed significantly higher CD4+ T cell counts.
This is in agreement with several previous reports showing
associations between Bw4 or Bw4-80I and protection from HIV-1
disease progression [9,10,26,27]. No previous study observed a
protective effect for C1. Recent studies identified a 235C single
nucleotide polymorphism near HLA-C that was associated with
HIV-1 control and increased expression of HLA-C [28,29],
however this variant was not associated with either group of C1 or
C2 alleles, nor could its effects be explained by one or more
individual HLA-C alleles [29,30]. Similarly, in our study, C1 did
not preferentially contain HLA-C alleles in known linkage with
235C (data not shown). Remarkably, in our study, the protective
effects of Bw4 and C1 appeared to be completely derived from
subjects harboring both genes. This could reflect the known
linkage disequilibrium between several HLA-B and HLA-C alleles
and their observed joint effects on HIV-1 control [31–33].
Interestingly, we noted a trend towards statistical interaction of
C1 with KIR2DS2 and KIR2DS3, which explained most of the C1
effect and resulted ina weakeningof the negativeeffects of KIR2DS2
and KIR2DS3 in the presence of C1. No statistical interaction could
be detected between C1 and inhibitory KIR2DL2 or KIR2DL3,
despite in vitro evidence of C1 binding to KIR2DL2/3 but not
KIR2DS2/3 [4,24,25]. It is plausible, however, that the interaction
of C1 with KIR2DL2/3 appeared neutral because only 2 subjects in
our study population lacked both KIR2DL2 and KIR2DL3, and thus
that the presence of C1 was the only limiting factor in establishing
the effect. Hence, we speculate that the weakening of the negative
effects of KIR2DS2 and KIR2DS3 by C1 is mediated by its
interaction withKIR2DL2/3. Thisconclusionconcurs withprevious
reports showing a link between KIR2DS1 and KIR2DS2 and risk for
developing psoriaticarthritis, particularly intheabsence ofthe HLA
ligands for their homologous inhibitory receptors, KIR2DL1 and
KIR2DL2/3 [34,35]. Previously, Martin et al observed a similar
statistical interaction between Bw4-80I and KIR3DS1 influencing
HIV-1 disease progression, however, in contrast to the tempering
effectsnotedinthepresentstudy,theBw4-80I/KIR3DS1 interaction
term completely inversed the negative effects of KIR3DS1 now
resulting in significant protection from disease progression [10].
Unfortunately, subsequent studies could not confirm this epistatic
Bw4-80I/KIR3DS1 interaction [11,12], and in the present study we
did not have sufficient numbers of subjects with KIR3DS1 to
replicate these calculations.
Group B KIR haplotypes are considered to be more activating than
group A haplotypes due to the higher numbers of activating KIR
genes that they contain [3,6]. Indeed, subjects with a KIR AB
genotype were shown to display higher NK cell responsiveness than
those with an AA genotype [36]. On the other hand, HLA Bw4 and
C1/2 ligands for inhibitory KIR provide the necessary inhibitory
signals that set the NK cell activation threshold and guarantee self-
tolerance [3,6]. Consequently, our data suggest that KIR and HLA
genotypes that favor NK cell activation, like carriage of a group B
KIR haplotype and/or lack of a Bw4 or C1 inhibitory KIR ligand,
play a detrimental role in the progression of HIV-1 disease. This
conclusion is at variance with previous reports by Martin et al, in
Figure 2. Effect of KIR and HLA genotypes on the rate of CD4+ T cell decline among HIV-1 infected subjects. Thin lines represent
individual CD4+ T cell count profiles (n=20). Thick lines represent the fitted models calculated by mixed-effects linear regression analysis. (A) Effects
of AA and Bx genotypes. (B) Effect of Bw4:C1 genotype. (C) Effect of Bx genotype in the absence of Bw4:C1. Bw4:C1 denotes the simultaneous
occurrence of Bw4 and C1. The estimated fold decrease in CD4+ T cell count per year and p values are shown.
doi:10.1371/journal.pone.0017043.g002
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progression was proposed [10,17]. In these studies, KIR3DS1/Bw4-
80I genotypes were suggested to directly activate NK cells [10],
while strongly inhibitory KIR3DL1/Bw4-80I genotypes were
hypothesized to display greater NK cell activation capacity due to
better NK cell licensing [17]. Indeed, subsequent in vitro studies
were able to show stronger NK-cell mediated virus inhibition,
functional capacity, and specific NK cell subset expansion during
acute HIV-1 infection for these genotypes [37–39]. However, other
studies found that Bw4 strongly inhibited proliferation and
cytotoxicity of KIR3DL1-expressing NK cellswithout any influence
on KIR3DS1 [16], and that possession of KIR3DS1 alone was
sufficienttoinducestrong NKcelleffectorfunctions [40].Infact,we
believe that our interpretation of a detrimental role for activating
KIR/HLA genotypes makes more sense in the light of emerging data
on innate immune activation during acute HIV-1 infection in
establishing HIV-1 pathogenesis. For instance, acute SIV infection
of non-progressing sooty mangabeys is characterized by substan-
tially reduced levels of innate immune activation, including lower
IFN-a production, IFN-regulated gene expression, and NK cell
proliferation, compared to that seen in AIDS progressing rhesus
macaques [41,42]. Like rhesus macaques, HIV-1 infected humans
show significant innate immune activation and expansion of NK
cells during the acute phase of the infection [43,44]. In agreement
with this, a recent study found only low levels of antiviral NK cell
activity together witha low frequency of KIR3DS1 in a group of rare
HIV-1 controller patients [45]. Although the possible pathogenic
mechanisms of carrying an activating KIR/HLA genotype remain
unclear, studies have shown direct NK cell-mediated killing of
CD4+ T cells that express NKp44L, a ligand for NKp44 that is
induced upon exposure to a HIV-1 gp41, to correlate with HIV-1
disease progression [46,47]. Alternatively, CD4+ and CD8+ T cells
are known to express KIR and could be involved as well.
Interestingly, we found that KIR/HLA genotypes correlated best
with the CD4+ T cell count and not, or at least much more
weakly, with the viral load of the study subjects. This is in
agreement with a previous KIR study noting better correlations
with disease outcomes involving the CD4+ T cell count than the
viral load [11]. In part, this could reflect the lower within-patient
variation for the CD4+ T cell count, and the fact that the CD4+ T
cell count shows a better clinical prognostic value than the viral
load, especially during the chronic phase of the infection (the
disease stage most of our study subjects are expected to be in) [48].
However, preferential correlations with the CD4+ T cell count
could also reflect the specific immune responses that are involved,
with activating KIR/HLA genotypes that drive cytotoxic responses
being expected to directly impact on target cell numbers. In that
respect, our data are in agreement with studies of SIV-infected
primate species showing a strong link between rapid control of
innate immune activation and lack of CD4 count depletion or
disease progression, however without any influence on the often
high levels of viral replication seen in these animals [41,42]. In this
model, we could hypothesize a role for viral load at the beginning
of the causal pathway, with viral peptides modulating the
interactions of activating and inhibitory KIR with their ligands,
within the context of the inherited KIR/HLA genotype [49,50].
Previously, we found that carriage of an AB KIR genotype and of
certain inhibitory KIR combinations in the absence of their Bw4 or
C1 ligands was associated with resistance to HIV-1 infection in the
same population of African female sex workers [51]. These findings
corroborated previous data of increased NK cell-mediated
cytotoxicity in HIV-1 resistant drug users [52], and have since
then been confirmed by several other studies showing phenotypic
and/or genotypic activating KIR profiles in HIV-exposed seroneg-
ative populations [53–55]. Interestingly, the genotypes observed in
our previous study are nearly the same as the ones identified here,
despite differences in study design and data analysis (e.g., all AB
genotypes in our previous study are actually Bx according to current
guidelines, and combinations of KIR2DL2 and KIR2DL3 coincide
withthe presenceofa AA orBx genotype). Together,this meansthat
in our population of African female sex workers, similar activating
KIR/HLA genotypes are associated with resistance to HIV
infection as well as with faster progression of the disease. This is
paradoxical, yet could be logically explained by an intriguing model
in which an activated NK cell profile protects the host against HIV-
1 acquisition through rapid and potent elimination of HIV-1
infected targetcells, but once systemically infected, promotes HIV-1
disease progression through over-activation of the innate and
adaptive arms of the immune system.
The observed associations between KIR/HLA genotype and
CD4+ T cell count in this study were detected by a cross-sectional
analysis of therapy-naı ¨ve HIV-1 infected female sex workers. This
approach is less sensitive than a longitudinal analysis of time to
AIDS and it could be biased by the unknown duration of infection
of the included subjects. To address this, we first used the total
duration of commercial sex work, the main risk factor for HIV-1
infection in this population, as an estimate of the time since
infection,and found that adjustment had no impacton the observed
associations. Secondly, we calculated the longitudinal effects of the
KIR/HLA genotypes on the rate of CD4+ T cell decline in a
subgroup of female sex workers with available follow-up. This
analysis confirmed the cross-sectional associations, however it was
ratherlimited innumberofincluded subjectsaswell asinnumberof
follow-up samples. Thus, confirmation of our findings in larger
longitudinal cohorts of untreated HIV-infected subjects remains
warranted. Furthermore, future functional studies should investi-
gate whether activating KIR profiles are expressed on NK cells,
CD8+ T cells, or both, and to what extent the activating KIR/HLA
genotypes proposed in this study translate into increased in vivo
immune activation and enhanced in vitro target cell cytotoxicity.
In summary, we found that group B KIR haplotypes and lack of
specific inhibitory KIR ligand genes, genotypes considered to
favor NK cell activation, are associated with CD4+ T cell loss
during HIV-1 infection. Better understanding of how genetic
variation at KIR and HLA loci influences HIV-1 pathogenesis may
lead to the development of immune intervention strategies aiming
at controlling progression of the disease.
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